Evolving Standards of Care

Posted: August 14, 2019 People diagnosed with lung cancer do not have to live close to a major cancer center to get a second opinion from one of its experts, thanks to a growing number of remote second-opinion (RSO) programs. “What is offered in remote second-opinion programs can vary, but the one commonality is that the…

Posted: May 27, 2019 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a large umbrella trial evaluating patients with early-stage NSCLC who have undergone complete tumor resection. As a whole, the trial will examine the role of erlotinib for those patients with EGFR mutations, crizotinib for those patients who have ALK rearrangements, and…

By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances in context, I remember the early days (1970s) of lung cancer research at the National Cancer Institute, when we conducted 12 consecutive phase II trials…

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to available therapies for malignant pleural mesothelioma (MPM). Luckily, a renewed interest in MPM with emphasis on immunotherapy has led to several phase II and III…

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that the IASLC-LATAM (Latin American) Group organized a BWLCC in Lima. More than 160 attendees were provided with the most scientifically important presentations from the IASLC…

Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes in the study and management of all forms of lung cancer. Dr. Hanna spoke with the IASLC Lung Cancer News in detail about the questions—…

By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. Food and Drug Administration for the treatment of advanced ALKpositive lung cancer. The approval represents a significant advance for patients with ALK-positive lung cancer. Given…

By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care unit (ICU) have improved during the past 2 decades. In recent studies, ICU mortality for those patients admitted on an unscheduled basis was 30% to…

Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have deeply changed the second-line treatment of patients with advanced NSCLC, with three newly registered drugs in only a few years. Immune checkpoint inhibitors are also…

By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it make a difference in stage 1 nonsmall cell lung cancer? AATS 2018; Abstract 67. Pathologic upstaging of NSCLC occurs in an estimated 14% to 25% of…